Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women

Authors: Su Yon Jung, Eric M. Sobel, Jeanette C. Papp, Zuo-Feng Zhang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Impaired glucose metabolism–related genetic variants and traits likely interact with obesity and related lifestyle factors, influencing postmenopausal breast and colorectal cancer (CRC), but their interconnected pathways are not fully understood. By stratifying via obesity and lifestyles, we partitioned the total effect of glucose metabolism genetic variants on cancer risk into two putative mechanisms: 1) indirect (risk-associated glucose metabolism genetic variants mediated by glucose metabolism traits) and 2) direct (risk-associated glucose metabolism genetic variants through pathways other than glucose metabolism traits) effects.

Method

Using 16 single-nucleotide polymorphisms (SNPs) associated with glucose metabolism and data from 5379 postmenopausal women in the Women’s Health Initiative Harmonized and Imputed Genome-Wide Association Studies, we retrospectively assessed the indirect and direct effects of glucose metabolism-traits (fasting glucose, insulin, and homeostatic model assessment–insulin resistance [HOMA-IR]) using two quantitative tests.

Results

Several SNPs were associated with breast cancer and CRC risk, and these SNP–cancer associations differed between non-obese and obese women. In both strata, the direct effect of cancer risk associated with the SNP accounted for the majority of the total effect for most SNPs, with roughly 10% of cancer risk due to the SNP that was from an indirect effect mediated by glucose metabolism traits. No apparent differences in the indirect (glucose metabolism-mediated) effects were seen between non-obese and obese women. It is notable that among obese women, 50% of cancer risk was mediated via glucose metabolism trait, owing to two SNPs: in breast cancer, in relation to GCKR through glucose, and in CRC, in relation to DGKB/TMEM195 through HOMA-IR.

Conclusions

Our findings suggest that glucose metabolism genetic variants interact with obesity, resulting in altered cancer risk through pathways other than those mediated by glucose metabolism traits.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society. Breast Cancer Facts & Figures 2015–2016. Atlanta: American Cancer Society Inc.; 2015.
2.
American Cancer Society. Global Cancer Facts & Figures 3rd Edition. Atlanta: American Cancer Society, Inc.;2015.
3.
Tenesa A, Campbell H, Theodoratou E, Dunlop L, Cetnarskyj R, Farrington SM, Dunlop MG. Common genetic variants at the MC4R locus are associated with obesity, but not with dietary energy intake or colorectal cancer in the Scottish population. Int J Obes. 2009;33(2):284–8.CrossRef
4.
Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr. 2011;93(2):234–42.PubMedCrossRef
5.
Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, Kong SY, Tsilidis KK, Weiderpass E, Bueno-De-Mesquita HB, et al. Plasma fetuin-a concentration, genetic variation in the AHSG gene and risk of colorectal cancer. Int J Cancer. 2015;137(4):911–20.PubMedCrossRef
6.
Lee SK, Moon JW, Lee YW, Lee JO, Kim SJ, Kim N, Kim J, Kim HS, Park SH. The effect of high glucose levels on the hypermethylation of protein phosphatase 1 regulatory subunit 3C (PPP1R3C) gene in colorectal cancer. J Genet. 2015;94(1):75–85.PubMedCrossRef
7.
Wairagu PM, Phan AN, Kim MK, Han J, Kim HW, Choi JW, Kim KW, Cha SK, Park KH, Jeong Y. Insulin priming effect on estradiol-induced breast cancer metabolism and growth. Cancer Biol Ther. 2015;16(3):484–92.PubMedPubMedCentralCrossRef
8.
Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013;12(24):3759–69.PubMedPubMedCentralCrossRef
9.
Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 2009;125(11):2704–10.PubMedCrossRef
10.
Vona-Davis L, Rose DP. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr Diabetes Rev. 2012;8(2):116–30.PubMedCrossRef
11.
Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012;130(4):921–9.PubMedCrossRef
12.
Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7(1):11–24.PubMedCrossRef
13.
14.
Argiles JM, Lopez-Soriano FJ. Insulin and cancer (review). Int J Oncol. 2001;18(4):683–7.PubMed
15.
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.PubMedPubMedCentralCrossRef
16.
Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2012;21(5):810–20.PubMedPubMedCentralCrossRef
17.
Feik E, Baierl A, Hieger B, Fuhrlinger G, Pentz A, Stattner S, Weiss W, Pulgram T, Leeb G, Mach K, et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control. 2010;21(1):91–7.PubMedCrossRef
18.
Kaabi B, Belaaloui G, Benbrahim W, Hamizi K, Sadelaoud M, Toumi W, Bounecer H. ADRA2A Germline Gene polymorphism is associated to the severity, but not to the risk, of breast cancer. Pathol Oncol Res. 2016;22(2):357–65.PubMedCrossRef
19.
Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, Shin A, Jee SH, Kim DH, Cai Q, et al. Large-scale genetic study in east Asians identifies six new loci associated with colorectal cancer risk. Nat Genet. 2014;46(6):533–42.PubMedPubMedCentralCrossRef
20.
Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, Valvano MR, Pazienza V, Merla G, Augello B, et al. Deregulated expression of cryptochrome genes in human colorectal cancer. Mol Cancer. 2016;15(1):6.PubMedPubMedCentralCrossRef
21.
Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumour Biol. 2015;36(5):3533–9.PubMedCrossRef
22.
Pechlivanis S, Wagner K, Chang-Claude J, Hoffmeister M, Brenner H, Forsti A. Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detect Prev. 2007;31(5):408–16.PubMedCrossRef
23.
Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013;33:46-51.
24.
Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19(6):R225–41.PubMedCrossRef
25.
Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Silva C, Rotellar F, Hernandez-Lizoain JL, Baixauli J, Valenti V, Pardo F, et al. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem. 2011;22(7):634–41.PubMedCrossRef
26.
Liu L, Zhong R, Wei S, Xiang H, Chen J, Xie D, Yin J, Zou L, Sun J, Chen W, et al. The leptin gene family and colorectal cancer: interaction with smoking behavior and family history of cancer. PLoS One. 2013;8(4):e60777.PubMedPubMedCentralCrossRef
27.
Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012;132(3):993–1000.PubMedCrossRef
28.
Wasserman L, Flatt SW, Natarajan L, Laughlin G, Matusalem M, Faerber S, Rock CL, Barrett-Connor E, Pierce JP. Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors. Int J Obes Relat Metab Disord. 2004;28(1):49–56.PubMedCrossRef
29.
Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1204–11.PubMedCrossRef
30.
Khoury-Shakour S, Gruber SB, Lejbkowicz F, Rennert HS, Raskin L, Pinchev M, Rennert G. Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3314–8.PubMedPubMedCentralCrossRef
31.
Seti H, Leikin-Frenkel A, Werner H. Effects of omega-3 and omega-6 fatty acids on IGF-I receptor signalling in colorectal cancer cells. Arch Physiol Biochem. 2009;115(3):127–36.PubMedCrossRef
32.
Slattery ML, Lundgreen A, Herrick JS, Caan BJ, Potter JD, Wolff RK. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment. Nutr Cancer. 2011;63(8):1226–34.PubMedPubMedCentralCrossRef
33.
34.
Weichhaus M, Broom J, Wahle K, Bermano G. A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer. Int J Oncol. 2012;41(2):745–52.PubMed
35.
Simons CC, van den Brandt PA, Stehouwer CD, van Engeland M, Weijenberg MP. Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1852–62.PubMedCrossRef
36.
Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer. 2005;115(1):148–54.PubMedCrossRef
37.
The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative study group. Control Clin Trials. 1998;19(1):61–109.CrossRef
38.
39.
National Cancer Institute. SEER Program: Comparative Staging Guide For Cancer. 1993.
40.
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105–16.PubMedPubMedCentralCrossRef
41.
Ingelsson E, Langenberg C, Hivert MF, Prokopenko I, Lyssenko V, Dupuis J, Magi R, Sharp S, Jackson AU, Assimes TL, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59(5):1266–75.PubMedPubMedCentralCrossRef
42.
Nettleton JA, Hivert MF, Lemaitre RN, McKeown NM, Mozaffarian D, Tanaka T, Wojczynski MK, Hruby A, Djousse L, Ngwa JS, et al. Meta-analysis investigating associations between healthy diet and fasting glucose and insulin levels and modification by loci associated with glucose homeostasis in data from 15 cohorts. Am J Epidemiol. 2013;177(2):103–15.PubMedCrossRef
43.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef
44.
45.
Mackinnon DP, Warsi G, Dwyer JH. A simulation study of mediated effect measures. Multivar Behav Res. 1995;30(1):41.CrossRef
46.
Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods. 2002;7(4):422–45.PubMedCrossRef
47.
Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring). 2007;15(4):798–808.CrossRef
48.
Institute EB. 1000 genomes browser orientation. In: Based on Project Phase I Data. 2011.
49.
Guo T, Chen T, Gu C, Li B, Xu C. Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer. Tumour Biol. 2015;36(10):7649–58.PubMedCrossRef
50.
Abbadi S, Rodarte JJ, Abutaleb A, Lavell E, Smith CL, Ruff W, Schiller J, Olivi A, Levchenko A, Guerrero-Cazares H, et al. Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion. Mol Cancer Res. 2014;12(11):1547–59.PubMedPubMedCentralCrossRef
51.
Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology. 2012;56(1):186–97.PubMedPubMedCentralCrossRef
52.
Nettleton JA, McKeown NM, Kanoni S, Lemaitre RN, Hivert MF, Ngwa J, van Rooij FJ, Sonestedt E, Wojczynski MK, Ye Z, et al. Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care. 2010;33(12):2684–91.PubMedPubMedCentralCrossRef
53.
Murad AS, Smith GD, Lewis SJ, Cox A, Donovan JL, Neal DE, Hamdy FC, Martin RM. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). Int J Mol Epidemiol Genet. 2010;1(3):175–83.PubMedPubMedCentral
54.
Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 2011;117(3):480–91.PubMedCrossRef
55.
Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011;28(10):841–51.PubMedCrossRef
56.
Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, Stefan N, Haring HU, Fritsche A. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008;51(4):597–601.PubMedCrossRef
Metadata
Title
Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women
Authors
Su Yon Jung
Eric M. Sobel
Jeanette C. Papp
Zuo-Feng Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3284-7

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients

Erratum

Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA

Research article

Prospective study of 11C–methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment

Research article

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Research article

CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer

Research article

Cancers of unknown primary diagnosed during hospitalization: a population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits